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PND41
DyNamics of Quality of life iN chilDreN with cystic fibrosis ageD 
5-16 years
Simonova O., Gorinova Y., Vinyarskaya I., Samsonova M., Chernikov V.
FSBI Scientific Center of Children’s Health, RAMS, Moscow, Russia
Objectives: For improvement of aiding effectiveness both for clinicians and spe-
cialists in the field of health care system one should know quality of patient’s life 
in different time period rating of the disease. MethOds: 70 cystic fibrosis (CF) 
children from Russia and CIS countries 5-16 years were interviewed using HUI ver-
sion 15Q, while children over 12 years responded on their own (self assessment), 
information about children younger 12 years was obtained from parents (proxy 
assessment) .Version was translated into russian language and adapted. HUI cur-
rently consists of two systems: HUI Mark 2 and HUI Mark 3. Each HUI2 and HUI3 
classification system consists of attributes (domains) of health and 3 to 6 levels of 
functional ability/disability within each attribute and is very responsive to changes 
and to highlight avenues of additional study. Single-attribute utility scores and 
multi-attribute utility scores evaluated corresponding to each system, ranges from 
0 to 1. Results: Mean Mark 2 has a tendency to increase from 0,85 in children 
5 years to 0,95 in children 15 years with reduction in 6 years (0,80), 12 years (0,85) 
and 16 years (0,85). Same tendency was observed in Mark 3: 6 years- 0,75; 12 years- 
0,75; 16 years- 0,77 cOnclusiOns: Decrease of quality of life in above mentioned 
ages is a result of unadequate treatment in children living in some regions of CIS 
and severe complications of CF in older children also.
PND42
health relateD Quality of life (hrQl) iN ParkiNsoN’s Disease: the 
imPact of ‘oN’ aND ‘off’ time
Kerr C1, Howard C.E1, Johnston K2, Smith H.T.3, Lloyd E3, Cooper J.A3, McIntosh E.4,  
Lloyd A.J.1
1Oxford Outcomes, An ICON plc Company, Oxford, UK, 2Oxford Outcomes, An ICON plc Company, 
Vancouver, BC, Canada, 3GSK, Brentford, UK, 4University of Glasgow, Glasgow, UK
Objectives: Diurnal variation in symptoms and functioning is a feature of 
Parkinson’s disease, referred to as ‘on’ and ‘off time’. Typically patient reported 
outcomes (PROs) don’t capture this variability or its value, instead requesting par-
ticipants report over the last day or week. This study evaluated the impact and value 
of ‘on’ and ‘off time’ for people with Parkinson’s (PwP) by assessing their HRQL and 
strength of preference. MethOds: PwP from UK, Spain, France and Italy (n= 305), 
experiencing ≥ 2 hours ‘off time’ daily, completed EQ-5D-5L assessments for ‘on’ 
and ‘off time’ that day, followed by a discrete choice experiment (DCE) evaluating 5 
treatment attributes: duration of ‘on time’; quality of ‘off time’; predictability of ‘off 
time’; feelings of anxiety/depression, and dosing frequency. The DCE was informed 
by qualitative work with patients (n= 20), carers (n= 6) and health professionals (n= 6) 
in UK and Spain and employed an orthogonal, factorial, fold-over design. Analysis 
used the mixed-logit model and effects coding of categorical levels (predictability of 
off-time attribute). Results: Mean EQ-5D utility values were significantly lower for 
‘off time’ (0.37, 95%CI: 0.33-0.40) than ‘on time’ (0.60, 95%CI: 0.57-0.62). All attributes 
were significant drivers of treatment choice. PwP valued increased duration of ‘on 
time’ (per hour per day: OR= 1.40, 95%CI 1.31-1.45) and predictability of ‘off time’ 
most highly (predictability to within 30 minutes of symptoms returning: OR= 1.42, 
95%CI 1.15-1.57). High disutility was reported for substantial unpredictablility of ‘off 
time’ (OR= 0.67, 95%CI 0.49-0.91). cOnclusiOns: Important differences in quality 
of life between ‘on’ and ‘off time’ were found which could be missed by standard 
PRO assessment, including the relative value that PwP placed on increased dura-
tion of ‘on time’ and predictability of ‘off time’. Assessments and interpretation of 
outcomes in Parkinson’s should consider diurnal variation. Capturing this variation 
and its value may require modifications to PRO design. [Study HO-11-802]
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cultural aDaPtatioN aND ValiDatioN to sPaNish of the “ms 
treatmeNt coNcerNs QuestioNNaire-mstcQ”
Galera J.1, Munteis E.2, Navarro G.3, Meca J.4, Maestre A.5, Perez A.6, Gracia J.7, Pato A.8
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Objectives: Albeit effectiveness of subcutaneous treatments for Multiple 
Sclerosis (MS) has been demonstrated, adverse reactions and pain may entail prob-
lems regarding treatment satisfaction and continuity. This study aims to adapt 
and validate the Spanish version of the “Multiple Sclerosis Treatment Concerns 
Questionnaire-MSTCQ”, which evaluates satisfaction with the injection device (ID) 
in 4 dimensions: Injection system (A), Side-effects (B) (flu-like symptoms, reactions, 
and satisfaction), Treatment experience (C) and Benefits (D). MethOds: Two Stages: 
1) Cultural adaptation: Forward-backward translation and expert (n= 6) and patient 
(n= 30) panels; 2) Validation: Observational, cross-sectional, multicenter study. A 
total of 143 adult patients suffering from MS and using an ID were evaluated. Tools 
employed: MSTCQ, Patient-Reported Indices for Multiple Sclerosis (PRIMUS), Treatment 
Satisfaction Questionnaire for Medication (TSQM), Morisky Green and Patient Injection 
Site Reaction (ISR) and Injection Site Pain (ISP). Psychometric properties: Feasibility 
(% valid cases and ground/ceiling effects); Reliability (Cronbach α ) and test-retest 
(41 patients, Intraclass Correlation Coefficient, ICC); as well as construct (Factorial 
analysis of dimensions A and B, FA) and convergent (Spearman MSTCQ vs. TSQM) 
validity. Results: Mean age(SD) in cases was 41,94(10,47) years, 63% female, 88,11% 
suffering from Relapsing-Remitting MS. MSTCQ feasibility was adequate (missing 
0%-2,80%). High internal consistency, total score (A+B) α = 0, 89, by dimensions α (A, 
B and C): 0,76, 0,89 and 0,92, respectively. Furthermore, a concordance was found 
between total (ICC= 0, 98) and by dimensions ICC (A, B and C) scores: 0,82, 0,97 and 
0,89, respectively. The FA confirms dimensions A and B from the original question-
naire. Lastly, the association between total and by dimensions scores, from MSTCQ 
and TSQM was, overall, moderately strong (Rho between-0, 74, y 0, 42) and significant 
isfaction and preferences for MS treatments. Bibliographic references were hand 
searched. English or Spanish studies published between January 2007 and January 
2013 were selected. Results: A total of 398 citations were identified; 12 studies 
accomplished the inclusion criteria. Six referred to PROs and treatment costs; 4 
analyzed satisfaction with disease-modifying therapies (DMTs) and 2 assessed pref-
erences for treatment attributes. An increased adherence and persistence on DMTs 
was associated to higher pharmacy costs and to better clinical outcomes [lower 
relapse risk (OR= 0.71 CI 95%, 0.59-0.85); decreased MS hospitalizations (OR= 0.63, 
CI 95%, 0.47 – 0.83)] leading to a cost reduction of up to 22% patient/year. DMT 
adherent patients had a significantly lower rate of severe relapses (12.5% vs. 19.5%; 
p= 0.0200), lower MS-related or all-causes medical (7.6% vs. 12.5%; p= 0.0447 and 
11.2% vs. 20.0%; p= 0.0027) and emergency visits (8.9% vs. 15.0%; p= 0.0215 and 34.6% 
vs. 43.5%; p= 0.0305) than non-adherent. MS-related and all-cause inpatient costs 
(354.77±2.485.03 vs. 853.13±3,635.48; p= 0.0270 and 648.71±3,753.74 vs. 62.51±265.23; 
p= 0.0018) as well as emergency visit costs (46.46±255.94 vs. 1,740.88±6,127.27; 
p= 0.0076 and 147.82±430.79 vs. 242.42±592.96; p= 0.0044) were significantly lower 
in adherent patients. Self-injection [Visual Analogue Scale (VAS) mean 6.9; range 
0-10] render higher treatment satisfaction. Slower disability progression (efficacy) 
was the most preferred attribute (p< 0,001). Newly developed electronic devices 
that allow adjusting injection settings as well as adherence objective monitoring 
appeal more to patients (VAS mean 7.7; range 0-10) than more traditional methods 
of administration. cOnclusiOns: MS studies assessing adherence and costs are 
scarce. Treatments and devices better tailored to patients’ needs improve adherence, 
enhance clinical outcomes and procure a reduction on MS costs.
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health state (Qaly) Values for multiPle sclerosis: a rePort usiNg 
Data from the uNiteD kiNgDom south west imPact of multiPle 
sclerosis (swims) stuDy
Green C.1, Hawton A.1, Zajicek J.2
1Exeter University, Exeter, UK, 2Plymouth University, Plymouth, UK
Objectives: To present health state values (QALY weights) for multiple scle-
rosis (MS) health states using data from a prospective, longitudinal, cohort 
study. MethOds: Data from a large UK cohort study for MS, the South West Impact 
of MS (SWIMS) Study, were used for analysis. SWIMS data comprise six-monthly 
self-report assessments, including EQ-5D and SF-36 health status measures, and 
data on relapse frequency/severity. Self-report data is supplemented with data 
from clinician assessment of disability using the EDSS. Health state valuation data 
are sourced from published UK tariffs (EQ-5D and SF-6D) to present values for MS 
against EDSS, relapse characteristics, and against other disease related characteris-
tics. Results: Analyses of SWIMS data included 1,441 respondents, over an average 
of 8 time-points. Findings on health state values show a health profile that wors-
ens by disease progression, against EDSS stages, using both the EQ-5D and SF-6D 
methods. Health state values estimated from EQ-5D data range from 0.76 at EDSS 
stage 1.0 to 0.03 at EDSS stage 8, with lower values seen for progressive MS. Values 
estimated from SF-36 data reflect the narrower range of values possible on the SF6D 
tariffs, with values from 0.7 to 0.53 across EDSS stages 1.0 to 8. Findings demonstrate 
impact on health state values due to relapse events, with this impact reported at 
0.08 using the EQ-5D and at 0.05 using the SF-6D. The impact of relapse frequency, 
severity and endurance on health has also been assessed. cOnclusiOns: This 
study presents health state valuation data derived from a high quality longitudinal 
cohort study, including values (QALY weights) for features/characteristics of relapse 
events in people with MS. This data can support improvements in the conduct of 
cost-effectiveness analyses of treatments for MS, and can be helpful in a general 
health policy context.
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caregiVer burDeN iN fragile X syNDrome as a fuNctioN of a health 
state utility iNDeX iN the uNiteD states
Raspa M.1, Bishop E.2, Candrilli S.D.3, Mitra D.3, Sacco P.4, Petrillo J.4, Bailey D.1
1RTI International, Research Triangle Park, NC, USA, 2RTI International, Atlanta, NC, USA, 3RTI 
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Objectives: To assess the association between burden experienced by caregivers 
of patients with fragile X syndrome (FXS) in the United States and a health state 
utilities index derived from the Aberrant Behavior Checklist-Community (ABC-
C). MethOds: A total of 340 US caregivers of children with FXS completed a ques-
tionnaire that captured information on FXS-related burden (i.e., specialist visits, 
medical tests, medications, financial burden, employment status, paid and unpaid 
caregiving, caregiver injuries, and mental health). Using the ABC-Utility Index 
(ABC-UI), an estimate of health-related quality-of-life derived from the ABC-C, five 
utility index categories were created: very low (0.00–0.33); low (0.34–0.66); moderate 
(0.67–0.77); high (0.78–0.89); and very high (0.90–1.00). After controlling for sex, age, 
overall ability level, and income, multivariable regression models documented the 
association between utility score and the nine burden-related outcomes. Results: 
Respondents (283 with FXS male child; 57 with FXS female child) were mostly female 
(91%), Caucasian (92%), and married (84%), with mean age of 50 years. Approximately 
2% of individuals with FXS were in the very low utility category, 30.6% low, 27.1% 
moderate, 37.6% high, and 2.6% very high. The mean utility score was 0.71. Females 
with FXS and adults ≥ 18 years had higher health utilities. Results from regression 
models indicate that increasing utility values reduced the likelihood of ≥ 5 (vs. < 5) 
specialist visits (b= -4.583; p< 0.001) and ≥ 2 (vs. 0 or 1) prescription medications 
used (b= -4.517; p< .001). Similarly, increasing utility score was associated with a 
decreased likelihood of ≥ 8 (vs. < 8) hours of unpaid caregiving (b= -2.723; p= 0.003), 
≥ 1 (vs. 0 or 1) caregiver injuries (b= -7.540; p< 0.001), and ≥ 1 (vs. 0) mental health 
provider visits (b= -2.613; p= 0.002). cOnclusiOns: The ABC-UI appears to function 
well as a health-related quality-of-life indicator in individuals with FXS. Among 
caregivers of patients with FXS in the US, significant differences in burden exist 
across health state utilities.
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A prospective multinational, multicenter (84 centers in 22 countries), observational, 
post-marketing, longitudinal study (ULIS-2), investigating routine use of BoNT-A for 
treating post-stroke ULS. Primary outcome: achievement of the patient’s primary 
goal for treatment using Goal Attainment Scaling (GAS). Goals were set together by 
physicians and patients/caregivers. Patients were able to rate goals for importance. 
Secondary outcome: global assessment of benefits by both physician and patients/
caregiver. Results: Among the 456 adults with post-stroke ULS presenting for 
treatment with BoNT-A, the most commonly selected primary treatment goals were 
passive function (132 (28.9%)), active function (104 (22.8%)), pain (61 (13.4%), and 
impairment (105 (23%)). Patients rated 404/456 primary goals (88.6 %) as “impor-
tant” (395/456 (86.6%) as “very” or “moderately” important), indicating high patient 
involvement in goal-setting. Overall, 363 (79.6%) (95% CI 75.6% to 83.2%) patients 
achieved (or overachieved) their primary goal. GAS T-scores were strongly correlated 
with rating of global benefit and other standard measures (correlations of 0.38 
and 0.63, respectively; p< 0.001). cOnclusiOns: Patient-centered goal setting and 
evaluation using GAS to calculate changes of health-related status is a feasible way 
to capture changes in ULS patient experience. GAS as primary outcome measure in 
ULIS-2 is a step closer to a PRO in ULS patients.
PND47
PatieNt PrefereNces aND Priorities for aNti-ePilePtic Drug 
treatmeNt
Fargher E.A.1, Marson A.2, Jacoby A.3, Ring A.3, Williamson P.3, Hughes D.A.1
1Bangor University, Bangor, UK, 2Walton Centre for Neurology and Neurosurgery Foundation 
Trust, Liverpool, UK, 3University of Liverpool, Liverpool, UK
Objectives: Clinical trials in epilepsy may not routinely prioritise patient-oriented 
outcomes that consider the harms of treatments in addition to their benefits. To 
date, no systematic empirical research has been undertaken to assess the views of 
people with epilepsy about treatment outcomes. The aim was to identify which out-
comes of drug treatment are considered important to three groups of adults with 
epilepsy: (i) recently diagnosed, (ii) established diagnosis, (iii) women of childbearing 
age. MethOds: Semi-structured individual interviews containing ranking exercise 
were used to explore views and interpretations of benefits, harms, and potential life-
impacts of anti-epileptic drug treatments (n= 41); the feasibility of these findings were 
evaluated in focus groups of health care professionals responsible for prescribing anti-
epileptic drugs (n= 8) . Outcomes ranked 1-4 were scored 4-1. For each group, scores 
were summed and divided by the number of participants. Results: Ten recently diag-
nosed men (mean age 45.9), 13 established (mean age 39.3, 92% male), and 18 women of 
childbearing age (mean age 34.5) participated. Reduction in seizure frequency was the 
most highly ranked outcome of drug treatment across all three subgroups (women of 
childbearing age [score]= 2.5, recent= 2.4, established= 2.23). Adults recently diagnosed 
were most concerned about feelings of aggression (1.6), depression (1.0) and ability to 
work (0.9). Adults with established epilepsy were most concerned with ability to work 
(1.15) negative impacts on relationships (1.0), memory problems (0.69), and social-
life (0.69). Women of childbearing age were concerned about memory (1.22), reduced 
independence (0.78), feeling in control (0.56) and foetal abnormality (0.5). Clinicians 
considered life-impacts (eg work, relationships, independence) as consequences of 
benefits and harms of treatment. cOnclusiOns: The importance of remission from 
seizure was consistent. However, patients’ rankings of unfavourable outcomes of drug-
treatment varied by subgroup. Selection of outcome measures in clinical trials in epi-
lepsy must consider relevant patient-oriented outcomes which differ by population.
PND48
eValuatiNg fatigue iN fibromyalgia: DeVeloPmeNt aND ValiDatioN of 
the Daily Diary of fatigue symPtoms iN fibromyalgia (Dfs-fibro)
Burbridge C.1, Symonds T.1, Humphrey L.2, Arbuckle R.2, Hirsch I.3, Whelan L.1
1Pfizer Ltd., Surrey, UK, 2Adelphi Values, Bollington, UK, 3Astra Zeneca, Cheshire, UK
Objectives: Despite being recognised as an important symptom in Fibromyalgia 
(FM), existing measures of fatigue are unlikely to meet regulatory standards for clini-
cal trial endpoints. We therefore describe the development and validation of a new, 
electronically administered patient reported outcome (ePRO) measure of fatigue in FM 
- the Daily Diary of Fatigue Symptoms-Fibromyalgia (DFS-Fibro). This was developed in 
accordance with the FDA regulatory guidance and ISPOR good practice recommenda-
tions for the development and validation of PROs. MethOds: Initial item generation 
was based on concept elicitation interviews with 40 FM patients (from the US, Germany 
and France), and clinical relevance of the findings was confirmed by expert clinician 
review. The draft tool was pilot tested with 20 FM patients for 5-9 days, followed by 
cognitive debriefing interviews. A methodology study with 145 FM patients then fol-
lowed, providing data to conduct the psychometric validation of the measure. Both the 
qualitative and quantitative findings were used to finalise the DFS-Fibro. Results: 
Twenty-three items were generated from concept elicitation interviews, including 
items focussed on the physical and cognitive impacts of fatigue as well as fatigue 
‘symptom’ items. Some minor wording revisions were made following pilot testing 
and cognitive debriefing, but none were deleted. All patients found the measure easy 
to understand and use. Initial psychometric analyses supported removing items previ-
ously identified as candidates for deletion in the qualitative work, resulting in a 5-item 
measure focussed on the core symptom of FM fatigue. The psychometric analyses 
were then repeated on the final 5-item measure, which had very high internal consist-
ency (alpha = 0.99), strong test-retest reliability (r > 0.84), and met a priori criteria for 
convergent and known groups validity. cOnclusiOns: The DFS-Fibro development 
followed accepted guidelines and demonstrates strong psychometric properties and 
content validity as a measure of the symptom of fatigue in FM.
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eValuatiNg PatieNt aDhereNce rates to aPProVeD Disease moDifyiNg 
theraPies (Dmt) for relaPsiNg-remittiNg ms (rrms): oPeratioNal 
setuP for a multi-couNtry, multi-ceNter stuDy
Apecechea de Scheffer M., Faber S., Potthoff P., Eichmann F.
Kantar Health Germany, Munich, Germany
(p< 0,05; p< 0,01). cOnclusiOns: The Spanish version of the MSTCQ questionnaire 
is a feasible, reliable and valid tool for the evaluation of satisfaction with the injec-
tion device in the treatment of MS.
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Objectives: Diagnosing epilepsy is a lengthy and burdensome process for patients 
and their family. Although the need for a more patient-centered approach in clini-
cal practice is widely acknowledged, empirical evidence regarding patient prefer-
ences for diagnostic modalities in epilepsy is missing. The objectives of this study 
are 1) to identify to what extent important attributes of diagnostic procedures in 
epilepsy affect preferences for a procedure; 2) to determine the relative importance 
of these attributes; and 3) to calculate overall utility scores for routine electroen-
cephalography (EEG) and magnetoencephalography (MEG) registrations. MethOds: 
A discrete choice experiment was performed to determine patients’ preferences, 
which involved presentation of pair-wise choice tasks regarding hypothetical sce-
narios. Scenarios varied along six attributes: “Way of measuring brain activity”; 
“Duration”; “Freedom of movement”; “Travel time”; “Type of additional examina-
tion”; and “Chance of additional examination”. Choice tasks were constructed using 
a statistically efficient design and the questionnaire contained 15 unique unlabeled 
choice tasks. Mixed multinomial logistic regression was used to estimate patients’ 
preferences. Results: A total of 289 questionnaires were included in the analysis. 
McFadden’s pseudo R2 showed a model fit of 0.28 and all attributes were statistically 
significant. Heterogeneity in preferences was present for all attributes. “Freedom 
of movement” and “Chance of additional examination” were perceived as the most 
important attributes. Overall utility scores marginally differ between MEG and 
routine EEG. cOnclusiOns: Our study suggests that the identified attributes are 
important in determining patients’ preference for epilepsy diagnostics. It can be 
concluded that MEG is not necessarily more patient-friendly than a routine EEG in 
primary diagnostics and, regarding additional diagnostics, patients have a strong 
preference for long-term 24h EEG over EEG after sleep deprivation. Furthermore, 
barring substantial heterogeneity within the parameters in mind, our study sug-
gests that it is important to take individual preferences into account in clinical 
decision-making.
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Quality of life outcomes iN multiPle sclerosis: a reView of the 
literature
Rouse M., McKenna S., Twiss J., Graham J.E., Wilburn J.
Galen Research Ltd., Manchester, UK
Objectives: Multiple sclerosis (MS) is a chronic neurodegenerative disease affecting 
the central nervous system. There are a variety of symptoms and activity limitations 
associated with MS including mobility problems, muscle spasticity, fatigue and 
mental health problems. In order to gain an accurate insight into the impact of MS 
on patients it is important for accurate patient-reported outcome (PRO) instruments 
to be applied. The purpose of this review was to evaluate the available MS-specific 
PRO measures. MethOds: The online literature databases PubMed, Psychinfo and 
Web of Science were used for the search. The search identified all studies that used 
a PRO measure in the study design and was restricted to publications from the 
last fifteen years. Only measures used in at least three clinical trial studies were 
included. The measures identified were evaluated in terms of; source of items, 
item reduction methods, unidimensionality, practicality, responsiveness, reliability, 
internal consistency and face, content and construct validity. Results: The search 
yielded 2317 articles, of which 1066 were duplicates and removed. The review of the 
remaining articles identified six measures that met the review criteria: MSIS-29, 
LMSQoL, MSQoL-54, HAQUAMS, MSQLI and PRIMUS. In addition, the MUSIQoL was 
reviewed because of recent development activity. Most of the measures exhibited 
some weaknesses. Only the PRIMUS performed well on all the review criteria. It 
was the only measure to apply a clear theoretical framework and meet the strict 
measurement requirements of the Rasch model. cOnclusiOns: The PRIMUS is 
recommended for use in clinical trials. The review suggests that many clinical trials 
are using PROs that have not benefitted from the use of Item Response Theory and 
modern psychometric approaches.
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Muscle spasticity following stroke may interfere with motor and activity perfor-
mance, cause pain, and lead to secondary complications. Goals of spasticity man-
agement include improving function (active and passive) and body image, and 
facilitating concomitant treatments. The efficacy of BoNT-A in upper limb spasticity 
(ULS) patients focusing on reduction of muscle tone and pain is well established. 
However, there are no specific ULS patient-reported outcome measures (PROs) avail-
able. As patients with ULS are highly heterogeneous, there is a need to develop meas-
ures to capture realistic, patient-specific treatment goals. Objectives: To assess 
effectiveness of BoNTA on ULS considering patient-specific experience. MethOds: 
